Brilacidin

N/A

Report date: 2022/07/19 16:22:54
NMEQIDP

Base Information

Drug NameBrilacidin
Drug Alias Name布拉菌素Brilacidin-OM布瑞拉菌素BrilacidinaBrilacidine +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCell membrane permeability enhancersPhosphodieterase 4 inhibitors
TargetsPhosphodieterase 4
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)MucositisHead and Neck Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCellceutix Pharma
China Registration ClassN/A

Develop Information

Active CompaniesInnovation Pharmaceuticals IncAlfasigma Spa
Inactive CompaniesPolymedix IncCellceutix Corporation
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsMucositisHead and Neck NeoplasmsSkin Diseases, Infectious +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG